{"filing":{"accession_number":"0001636282-26-000105","cik":"0001636282","ticker":"SYRE","company_name":"Spyre Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-25","report_date":"2026-08-25","primary_document":"syre-20260825.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000105/syre-20260825.htm"},"events":[{"id":29447,"run_id":26966,"accession_number":"0001636282-26-000105","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Spyre announced topline results from the Phase 2 SKYWAY-RA sub-study of SPY072, demonstrating statistically significant efficacy on primary and secondary endpoints with a favorable safety profile. However, the magnitude of effect did not meet the company's internal bar to prioritize advancement of SPY072 as a monotherapy in rheumatoid arthritis, resulting in a strategic decision to deprioritize this development program.","company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","filing_date":"2026-08-25","form":"8-K","submitted_at":null,"items":[{"id":31733,"accession_number":"0001636282-26-000105","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Spyre announced topline results from the Phase 2 SKYWAY-RA sub-study of SPY072, a clinical-stage asset. While the drug demonstrated statistically significant efficacy on primary and secondary endpoints with a favorable safety profile, the company explicitly stated the \"magnitude of effect did not meet the Company's target to prioritize monotherapy development of SPY072 in rheumatoid arthritis.\" This is a material clinical development milestone that affects investor assessment of the company's pipeline strategy and resource allocation, but it is not a traditional earnings release (no financial results) nor a specific operational category like workforce reduction or material contract. The disclosure centers on clinical trial results and the strategic decision to deprioritize a program, making it an operational/strategic business event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T20:06:54.788887+00:00","company_name":"","ticker":null,"filing_date":""},{"id":31734,"accession_number":"0001636282-26-000105","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Spyre announced topline results from the Phase 2 SKYWAY-RA sub-study of SPY072, a clinical-stage asset. While the drug demonstrated statistically significant benefits on primary and secondary endpoints with a favorable safety profile, the company explicitly stated the results \"did not meet the Company's internal bar to prioritize advancement of SPY072 as a monotherapy in RA.\" This is a material clinical development milestone that affects investor assessment of the company's pipeline strategy and resource allocation, but it is neither a traditional earnings release nor a specific operational category—it is a clinical trial outcome that informs the company's go/no-go decision on a development program.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T20:06:54.788887+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31733,"accession_number":"0001636282-26-000105","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Spyre announced topline results from the Phase 2 SKYWAY-RA sub-study of SPY072, a clinical-stage asset. While the drug demonstrated statistically significant efficacy on primary and secondary endpoints with a favorable safety profile, the company explicitly stated the \"magnitude of effect did not meet the Company's target to prioritize monotherapy development of SPY072 in rheumatoid arthritis.\" This is a material clinical development milestone that affects investor assessment of the company's pipeline strategy and resource allocation, but it is not a traditional earnings release (no financial results) nor a specific operational category like workforce reduction or material contract. The disclosure centers on clinical trial results and the strategic decision to deprioritize a program, making it an operational/strategic business event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T20:06:54.788887+00:00","company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","filing_date":"2026-08-25"},{"id":31734,"accession_number":"0001636282-26-000105","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Spyre announced topline results from the Phase 2 SKYWAY-RA sub-study of SPY072, a clinical-stage asset. While the drug demonstrated statistically significant benefits on primary and secondary endpoints with a favorable safety profile, the company explicitly stated the results \"did not meet the Company's internal bar to prioritize advancement of SPY072 as a monotherapy in RA.\" This is a material clinical development milestone that affects investor assessment of the company's pipeline strategy and resource allocation, but it is neither a traditional earnings release nor a specific operational category—it is a clinical trial outcome that informs the company's go/no-go decision on a development program.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T20:06:54.788887+00:00","company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","filing_date":"2026-08-25"}]}